Lawmakers: NIH, FDA bill 'fiscally responsible, meaningful reform'
This article was originally published in Scrip
Heading into a crucial vote later this week by the full House, the authors of a massive bill aimed at overhauling the US biomedical enterprise – the 21st Century Cures Act – tried to get in front of expected criticism by fiscal conservatives on 6 July by insisting the legislation, which would give the FDA and the National Institutes of Health (NIH) added funding, ultimately would save the nation billions of dollars.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.